Keyword: Denali Therapeutics
Cleveland Clinic researchers depleted BACE1 to reverse amyloid plaque formation in mice with Alzheimer's disease.
Hard on the heels of a big IPO and a lucrative deal with Takeda, one of Denali’s top execs is leaving the company to join anti-aging startup Alkahest.
Takeda has struck two deals this morning as it looks to make good on its ongoing R&D reorganization.
While 2016 was a year of cancelled and low-end IPOs, 2017 was a year marked by IPO momentum.
The IPO sets Denali up to push drugs against Alzheimer’s and Parkinson’s diseases through early clinical trials.
Heavily backed biotechs Denali Therapeutics and Odonate Therapeutics are looking to make hay while the sun shines by filing for two big IPOs.
Bristol-Myers Squibb has dropped its option to buy single-asset cancer biotech F-star Alpha.
The third quarter saw more money being pumped into the biotech sphere through venture funds than Q2, but the number of deals were slightly down.
Investors have plowed another $130 million into a Series B to back the startup that’s led by Genentech vets, which brings its total raised to almost $350 million.